Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06108063
PHASE1/PHASE2
Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
Sponsor: Steadman Philippon Research Institute
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-03-06
Completion Date
2027-06-30
Last Updated
2024-03-12
Healthy Volunteers
No
Conditions
Interventions
DRUG
Losartan
12.5 mg oral Losartan taken for 28 days total (4 week postoperative).
DRUG
Placebo - Losartan
Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
Locations (1)
The Steadman Clinic
Vail, Colorado, United States